Authors:
Hartmann, JT
Fossa, SD
Nichols, CR
Droz, JP
Horwich, A
Gerl, A
Beyer, J
Pont, J
Fizazi, K
Hecker, H
Kanz, L
Einhorn, L
Bokemeyer, C
Citation: Jt. Hartmann et al., Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors, J NAT CANC, 93(22), 2001, pp. 1733-1738
Authors:
Hartmann, JT
Einhorn, L
Nichols, CR
Droz, JP
Horwich, A
Gerl, A
Fossa, SD
Beyer, J
Pont, J
Schmoll, HJ
Kanz, L
Bokemeyer, C
Citation: Jt. Hartmann et al., Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: Results of an international multicenter analysis, J CL ONCOL, 19(6), 2001, pp. 1641-1648
Authors:
Fizazi, K
Tjulandin, S
Salvioni, R
Germa-Lluch, JR
Bouzy, J
Ragan, D
Bokemeyer, C
Gerl, A
Flechon, A
de Bono, JS
Stenning, S
Horwich, A
Pont, J
Albers, P
De Giorgi, U
Bower, M
Bulanov, A
Pizzocaro, G
Aparicio, J
Nichols, CR
Theodore, C
Hartmann, JT
Schmoll, HJ
Kaye, SB
Culine, S
Droz, JP
Mahe, C
Citation: K. Fizazi et al., Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: Prognostic factors and role of postsurgery chemotherapy-results from an international study group, J CL ONCOL, 19(10), 2001, pp. 2647-2657
Authors:
Rick, O
Bokemeyer, C
Beyer, J
Hartmann, JT
Schwella, N
Kingreen, D
Neureither, S
Metzner, B
Casper, J
Wandt, H
Hartmann, F
Schmoll, HJ
Derigs, G
Gerl, A
Berdel, WE
Kanz, L
Siegert, W
Citation: O. Rick et al., Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer, J CL ONCOL, 19(1), 2001, pp. 81-88
Authors:
Gerl, A
Muhlbayer, D
Hansmann, G
Mraz, W
Hiddemann, W
Citation: A. Gerl et al., The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors, CANCER, 91(7), 2001, pp. 1297-1303
Authors:
Bokemeyer, C
Droz, JP
Horwich, A
Gerl, A
Fossa, SD
Beyer, J
Pont, J
Schmoll, HJ
Kanz, L
Einhorn, L
Nichols, CR
Hartmann, JT
Citation: C. Bokemeyer et al., Extragonadal seminoma - An international multicenter analysis of prognostic factors and long term treatment outcome, CANCER, 91(7), 2001, pp. 1394-1401
Authors:
Kollmannsberger, C
Gerl, A
Schleucher, N
Beyer, J
Kuczyk, M
Rick, O
Gasper, J
Sosada, M
Rie, C
Kanz, L
Bokemeyer, C
Citation: C. Kollmannsberger et al., Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer, ANTI-CANC D, 11(7), 2000, pp. 535-539
Citation: A. Gerl et R. Schierl, Urinary excretion of platinum in chemotherapy-treated long-term survivors of testicular cancer, ACTA ONCOL, 39(4), 2000, pp. 519-522
Authors:
Steyerberg, EW
Keizer, HJ
Sleijfer, DT
Fossa, SD
Bajorin, DF
Gerl, A
de Wit, R
Kirkels, WJ
Koops, HS
Habbema, JDF
Citation: Ew. Steyerberg et al., Retroperitoneal metastases in testicular cancer: Role of CT measurements of residual masses in decision making for resection after chemotherapy, RADIOLOGY, 215(2), 2000, pp. 437-444
Authors:
Hartmann, JT
Nichols, CR
Droz, JP
Horwich, A
Gerl, A
Fossa, SD
Beyer, J
Pont, J
Einhorn, L
Kanz, L
Bokemeyer, C
Citation: Jt. Hartmann et al., The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors, CANCER, 88(11), 2000, pp. 2629-2635
Authors:
Fossa, SD
Stenning, SP
Gerl, A
Horwich, A
Clark, PI
Wilkinson, PM
Jones, WG
Williams, MV
Oliver, RT
Newlands, ES
Mead, GM
Cullen, MH
Kaye, SB
Rustin, GJS
Cook, PA
Citation: Sd. Fossa et al., Prognostic factors in patients progressing after cisplatin based chemotherapy for malignant non-seminomatous germ cell tumours, BR J CANC, 80(9), 1999, pp. 1392-1399